QuidelOrtho Corporation
QDEL
NASDAQ·Healthcare·Medical - Specialties·Mkt cap $952.6M
$13.97
▲ +0.29%
P/E
—
Mkt Cap
$952.6M
52-Wk Range
$9.92–$35.58
52-Week Range
$9.92 - $35.58
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 50.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Comprehensive diagnostic portfolio spanning the entire healthcare testing continuum
- Established distribution network across hospitals, laboratories, clinics, and retail pharmacies globally
- High switching costs and customer stickiness in laboratory and transfusion medicine settings
- Specialized expertise in immunohematology and molecular diagnostics with regulatory certifications
- Recurring revenue model through consumables and test reagents
Bear Case
1 risk
- Low volatility (beta 0.7).
Growth
Turning profitable
Increasing global demand for diagnostic testing driven by aging populations and chronic disease prevalence
Value
Fairly valued vs Medical Devices peers
Momentum
Stable
-3.5% over 3m
Quality
Strong
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying QDEL right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
AUG 6, 2026
Reported EPS of $0.13 vs -$0.05 consensus (+366.2% surprise). Revenue of $630.9M vs $618.7M expected (+2.0%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+366.2%
Revenue trend · last 8Q
—
-5%
-3%
-3%
-4%
+2%
-11%
+3%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$727.1M
$707.8M
$692.8M
$613.9M
$699.9M
$723.6M
$619.8M
$630.9M
Margins · last 8Q
Gross
—
Operating
—
Profit
-14.7%
Wall Street consensus
3 analysts · 0% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
0%
Hold
100%
Sell
0%
Median Price Target
—
Latest: Citi · Jul 8, 2026
vs Industry
How QDEL stacks vs Medical - Specialties
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related